[Six Months Outcome in Patients with Macular Edema Due to Retinal Vein Occlusion Treated with Ranibizumab].

PURPOSE: To assess the efficacy of intravitreal ranibizumab in the treatment of macular edema due to branch and central retinal vein occlusion for 6 month. SUBJECTS AND METHODS: This study was retrospective, 32 eyes with branch retinal vein occlusion (BRVO) and 15 eyes with central retinal vein occlusion (CRVO) treated with intravitreal ranibizumab injections were investigated. We estimated the changes in visual acuity, central retinal thickness and average number of injections over 6 month. We also investigated which pre-injection factors were important in patients who improved following a single-dose injection. RESULTS: The average number of injections was 1.9 in BRVO and 2.5 in CRVO. The visual acuity and central retinal thickness were improved in both BRVO and CRVO at 6 months, compared with those before injection. In patients with BRVO, it was indicated that the thinner the central fovea thickness prior to injection, the higher the rate of sustained effect following a single-dose administration. CONCLUSION: Intravitreal ranibizumab injection is effective for macular edema with retinal vein occlusion.